← Back to Clinical Trials
Recruiting NCT04630496

NCT04630496 Geriatric Thoracic Surgery Ambulation Challenge

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04630496
Status Recruiting
Phase
Sponsor Dana-Farber Cancer Institute
Condition Thoracic Diseases
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2021-08-25
Primary Completion 2025-12-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Fitbit

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2021-08-25 with a primary completion date of 2025-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is examining collecting data on steps walked (ambulation) per day by thoracic surgery patients over the age of 65 years-old before surgery. The name(s) of the study device involved in this study is: * Fitbit inspire

Eligibility Criteria

Inclusion Criteria: * Patients Aged ≥ 65 years * Who are preparing to undergo thoracic surgery at Brigham and Women's Hospital (BWH) Exclusion Criteria: * Patients who are completely non-ambulatory (i.e. wheelchair-bound-patients) \* * Those who lack capacity to consent due to cognitive disease. * Patient for which surgery is felt to be more urgent and therefore performed earlier then our required timeframe for intervention. * Patients with cardiac disease or angina for which formal cardiac testing is required for clearance. * Our exclusion criteria do not include patients with gait disturbances or those who require assistance devices for ambulation.

Contact & Investigator

Central Contact

Michael T Jaklitsch, MD

✉ mjaklitsch@bwh.harvard.edu

📞 617-732- 6988

Principal Investigator

Michael T Jaklitsch, MD

PRINCIPAL INVESTIGATOR

Brigham and Women's Hospital

Frequently Asked Questions

Who can join the NCT04630496 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Thoracic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04630496 currently recruiting?

Yes, NCT04630496 is actively recruiting participants. Contact the research team at mjaklitsch@bwh.harvard.edu for enrollment information.

Where is the NCT04630496 trial being conducted?

This trial is being conducted at Boston, United States, Boston, United States.

Who is sponsoring the NCT04630496 clinical trial?

NCT04630496 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Michael T Jaklitsch, MD at Brigham and Women's Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology